Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

Michael J. Morris, MD, medical oncologist, section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, discusses the efficacy of Lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

The phase 3 VISION trial (NCT03511664), which examined the addition of 177Lu-PSMA-617 to best standard-of-care therapy in patients with mCRPC, showed that the agent is safe and can prolong survival in a paradigm where few other therapeutic options are available, according to Morris. Additionally, quality-of-life data will soon read out and complement data already reported on other clinical end points of the study, Morris adds.

In addition to overall survival and radiographic progression-free survival, another important end point was time to first symptomatic skeletal event (SSE). The risk of SSEs was reduced by 50%. In the past, findings like this have been known to serve as the basis for the approval of other therapeutics in prostate cancer, Morris notes. Moreover, the prostate-specific antigen decline rate and the overall response rate were higher in the 177Lu-PSMA-617 arm vs the control arm. Collectively, data from the trial suggest that 177Lu-PSMA-617 plus standard-of-care therapy is superior to standard-of-care therapy alone for this patient population, Morris concludes.